TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A phase 2 trial of TGRX-678 in chronic myeloid leukaemia, run by Shenzhen TargetRx Co., Ltd., now recruiting.
Overview
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT06453902 by Shenzhen TargetRx Co., Ltd., with 40 participants planned, started 2024-07-15 and due to reach its primary completion in 2026-06-30. Interventions recorded: TGRX-678.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shares Shenzhen TargetRx and the tag pipeline.
- TrialThe Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TreatmentTGRX-326
Shares Shenzhen TargetRx and the tag pipeline.
- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialOpen-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.